Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aytu Biopharma (AYTU) Gross Profit (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Gross Profit for 12 consecutive years, with $9.6 million as the latest value for Q4 2025.

  • Quarterly Gross Profit fell 10.77% to $9.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $41.9 million through Dec 2025, down 5.24% year-over-year, with the annual reading at $45.8 million for FY2025, 6.57% down from the prior year.
  • Gross Profit for Q4 2025 was $9.6 million at Aytu Biopharma, up from $9.2 million in the prior quarter.
  • The five-year high for Gross Profit was $18.6 million in Q2 2023, with the low at $9.2 million in Q3 2025.
  • Average Gross Profit over 5 years is $12.8 million, with a median of $12.5 million recorded in 2021.
  • The sharpest move saw Gross Profit soared 44.77% in 2022, then plummeted 40.47% in 2024.
  • Over 5 years, Gross Profit stood at $12.3 million in 2021, then skyrocketed by 40.6% to $17.3 million in 2022, then fell by 15.56% to $14.6 million in 2023, then dropped by 26.14% to $10.8 million in 2024, then dropped by 10.77% to $9.6 million in 2025.
  • According to Business Quant data, Gross Profit over the past three periods came in at $9.6 million, $9.2 million, and $10.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.